Abstract 23P
Background
PMC-309 is a novel human monoclonal IgG1 antibody (mAb). It binds with human VISTA, an immune checkpoint protein, with the effect of regulating the immunological activity of myeloid cells such as MDSC or myeloid-derived immune cells, thereby improving the antitumor activities of immune cells. In addition to being a novel drug substance, PMC309 will be the first IgG1 monoclonal antibody to act synergistically with other immunotherapies to improve treatment efficacy.
Methods
In vitro T cell activity: human PBMC was employed for the evaluation of T cell activity, and was stimulated with or w/o PMC-309 in the presence of anti-CD3/28 Antibody. In vivo study: MC38-bearing human VISTA knock-in (KI) mice were employed for the assessment of the anti-tumor activity of PMC-309. The tumor infiltrated immune cells: Immune cells in the TME were evaluated by immunohistochemistry (IHC) or flow cytometry (FACS) analysis.
Results
PMC-309 binding to VISTA-expressing cells is highly selective and the selectivity is maintained even in the low pH conditions that mimic TME. PMC-309 enhances the secretion of IFN-gamma, TNF-alpha, and IL-2 in Mixed Lymphocyte Reaction (MLR) settings. In addition, PMC-309 promoted monocyte differentiation into M1 macrophage which stimulates proinflammatory cytokine secretion of T cells. For the in vivo study, PMC-309 was intravenously administrated in VISTA-KI mice. The tumor growth rate was suppressed accompanied by a synergistic effect with an anti-PD1 antibody. The anti-tumor activity was associated with enhanced T cell activation, increased secretion of pro-inflammatory cytokines, and increased penetration of cytotoxic T cells, but lowing immune-suppressive MDSC cells into TME as demonstrated with IHC analysis.
Conclusions
PMC-309 enhanced both T-cell activation and monocyte activation. PMC-309 increased the number of T cell infiltration while a decrease of MDSCs in the TME. PMC-309 in combination with chemotherapy or other IO drugs could address the high medical unmet needs of patients with drug resistance to currently available IO treatment options.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
PharmAbcine Inc.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09
513P - Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 09